---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-079656"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:34:35.793299+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Therapeutics appoints David McIntyre as CFO as Garth Lees-Rolfe resigns

## Summary
- Garth Lees-Rolfe resigned as CFO effective April 11, 2025; not due to any dispute with the Company.
- David McIntyre appointed CFO effective April 14, 2025; previously CFO of Anthos Therapeutics and partner at Apple Tree Partners.
- McIntyre receives $485,000 base salary, 45% target bonus, and 3,142,967 stock options.
- Lees-Rolfe to consult through Aug 15, 2025 at $33,333/month; options continue vesting.

## SEC filing metadata
- accession: 0001193125-25-079656
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312525079656/0001193125-25-079656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312525079656/d857709d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-079656
- JSON: https://secwatch.observer/filing/0001193125-25-079656.json
- Plain text: https://secwatch.observer/filing/0001193125-25-079656.txt

## Key facts
- Executive change
  David McIntyre was appointed as Chief Financial Officer at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective April 14, 2025, the Board appointed David McIntyre as Chief Financial Officer, principal financial officer and principal accounting officer of the Company (the “Appointment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312525079656/0001193125-25-079656-index.htm
- Executive change
  Garth Lees-Rolfe resigned as Chief Financial Officer at Inhibikase Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Effective April 11, 2025, Garth Lees-Rolfe resigned as Chief Financial Officer, principal financial officer and principal accounting officer of Inhibikase Therapeutics, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312525079656/0001193125-25-079656-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.